Lazard has played a pivotal role in a major biotech merger, guiding Vertex Pharmaceuticals in its strategic $4.9 billion cash acquisition of Alpine Immune Sciences.
This deal, the largest in Vertex’s history, signifies a significant shift towards enhancing its kidney disease treatment portfolio amid a surge in biotech sector transactions. Based in Boston, Vertex has
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
Continue with Facebook Continue with Google